title: Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE).
  
  
  METHODS
  PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software.
  
  
  RESULTS
  Totally 4 studies, including 527 patients, compared the efficacy and safety of DEB-TACE with cTACE. The DEB-TACE achieved fewer side effects in alopecia (p = 0.0002, RR = 0.05, 95% CI: 0.01-0.24) and myelosuppression (p = 0.009, RR = 0.32, 95% CI: 0.14-0.75). Meanwhile, there was no significant difference in efficacy evaluation including complete response (p = 0.16, RR = 1.36, 95% CI: 0.89-2.08), partial response (p = 0.48, RR = 1.14, 95% CI: 0.80-1.62), stable disease (p = 0.73, RR = 0.93,95% CI: 0.60-1.40), progressive disease (p 0.19, RR = 0.80, 95% CI: 0.56-1.12), objective response (p = 0.26, RR 0.91, 95% CI: 0.48-1.72) and disease control (p = 0.05, RR = 1.18, 95% CI: 1.00-1.39).
  
  
  CONCLUSIONS
  DEB-TACE shows similar therapeutic efficacy to cTACE method and fewer adverse events.
authors.forename: Yang
authors.initials: Y
authors.lastname: Hui
authors.forename: Tang
authors.initials: T
authors.lastname: Ruihua
authors.forename: Li
authors.initials: L
authors.lastname: Jing
authors.forename: Liu
authors.initials: L
authors.lastname: Yaxiong
authors.forename: Li
authors.initials: L
authors.lastname: Ji
authors.forename: Ye
authors.initials: Y
authors.lastname: Linjie
authors.forename: Shao
authors.initials: S
authors.lastname: Dongyan
authors.forename: Jin
authors.initials: J
authors.lastname: Mingliang
authors.forename: Huang
authors.initials: H
authors.lastname: Qingsheng
authors.forename: Shi
authors.initials: S
authors.lastname: Junling
mesh_terms: D000505:Alopecia / Q000139:chemically induced; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001158:Arteries; D001855:Bone Marrow Diseases / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000628:therapy*; D008863:Microspheres; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin